AbCellera Biologics (ABCL) Competitors

AbCellera Biologics logo
$9.66 -0.81 (-7.69%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$9.68 +0.01 (+0.14%)
As of 11/20/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ABCL vs. SMMT, HALO, BMRN, KYMR, and PCVX

Should you buy AbCellera Biologics stock or one of its competitors? AbCellera Biologics's main competitors and comparable companies include Summit Therapeutics (SMMT), Halozyme Therapeutics (HALO), BioMarin Pharmaceutical (BMRN), Kymera Therapeutics (KYMR), and Vaxcyte (PCVX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AbCellera Biologics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and AbCellera Biologics (NASDAQ:ABCL) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

AbCellera Biologics has higher revenue and earnings than Summit Therapeutics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Summit TherapeuticsN/AN/A-$1.08B-$1.07N/A
AbCellera Biologics$75.13M42.02-$146.41M-$0.48N/A

Summit Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -218.54%. AbCellera Biologics' return on equity of -15.35% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Summit TherapeuticsN/A -138.82% -117.11%
AbCellera Biologics -218.54%-15.35%-10.84%

In the previous week, Summit Therapeutics had 20 more articles in the media than AbCellera Biologics. MarketBeat recorded 31 mentions for Summit Therapeutics and 11 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.53 beat Summit Therapeutics' score of -0.55 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Summit Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
10 Negative mention(s)
6 Very Negative mention(s)
Negative
AbCellera Biologics
2 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summit Therapeutics presently has a consensus target price of $28.10, suggesting a potential upside of 182.41%. AbCellera Biologics has a consensus target price of $16.75, suggesting a potential upside of 73.31%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than AbCellera Biologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Summit Therapeutics
2 Sell rating(s)
5 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.56
AbCellera Biologics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.92

Summit Therapeutics has a beta of -1.49, meaning that its stock price is 249% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market.

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 81.8% of Summit Therapeutics shares are held by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

AbCellera Biologics beats Summit Therapeutics on 10 of the 16 factors compared between the two stocks.

How does AbCellera Biologics compare to Halozyme Therapeutics?

AbCellera Biologics (NASDAQ:ABCL) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

Halozyme Therapeutics has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbCellera Biologics$75.13M42.02-$146.41M-$0.48N/A
Halozyme Therapeutics$1.40B7.46$316.89M$3.9323.24

AbCellera Biologics has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

In the previous week, Halozyme Therapeutics had 13 more articles in the media than AbCellera Biologics. MarketBeat recorded 24 mentions for Halozyme Therapeutics and 11 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.53 beat Halozyme Therapeutics' score of 0.27 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AbCellera Biologics
2 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Halozyme Therapeutics
8 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Halozyme Therapeutics has a net margin of 26.93% compared to AbCellera Biologics' net margin of -218.54%. Halozyme Therapeutics' return on equity of 751.81% beat AbCellera Biologics' return on equity.

Company Net Margins Return on Equity Return on Assets
AbCellera Biologics-218.54% -15.35% -10.84%
Halozyme Therapeutics 26.93%751.81%23.84%

AbCellera Biologics presently has a consensus price target of $16.75, indicating a potential upside of 73.31%. Halozyme Therapeutics has a consensus price target of $110.17, indicating a potential upside of 20.60%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, equities analysts clearly believe AbCellera Biologics is more favorable than Halozyme Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AbCellera Biologics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.92
Halozyme Therapeutics
1 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.46

Summary

Halozyme Therapeutics beats AbCellera Biologics on 9 of the 17 factors compared between the two stocks.

How does AbCellera Biologics compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

BioMarin Pharmaceutical presently has a consensus price target of $87.22, indicating a potential upside of 44.38%. AbCellera Biologics has a consensus price target of $16.75, indicating a potential upside of 73.31%. Given AbCellera Biologics' stronger consensus rating and higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than BioMarin Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioMarin Pharmaceutical
1 Sell rating(s)
6 Hold rating(s)
15 Buy rating(s)
3 Strong Buy rating(s)
2.80
AbCellera Biologics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.92

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

BioMarin Pharmaceutical has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market.

In the previous week, BioMarin Pharmaceutical had 2 more articles in the media than AbCellera Biologics. MarketBeat recorded 13 mentions for BioMarin Pharmaceutical and 11 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.53 beat BioMarin Pharmaceutical's score of 0.52 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioMarin Pharmaceutical
5 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
AbCellera Biologics
2 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

BioMarin Pharmaceutical has a net margin of -0.52% compared to AbCellera Biologics' net margin of -218.54%. BioMarin Pharmaceutical's return on equity of 5.58% beat AbCellera Biologics' return on equity.

Company Net Margins Return on Equity Return on Assets
BioMarin Pharmaceutical-0.52% 5.58% 3.51%
AbCellera Biologics -218.54%-15.35%-10.84%

BioMarin Pharmaceutical has higher revenue and earnings than AbCellera Biologics. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioMarin Pharmaceutical$3.22B3.63$348.90M-$0.10N/A
AbCellera Biologics$75.13M42.02-$146.41M-$0.48N/A

Summary

BioMarin Pharmaceutical beats AbCellera Biologics on 10 of the 17 factors compared between the two stocks.

How does AbCellera Biologics compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

In the previous week, AbCellera Biologics had 7 more articles in the media than Kymera Therapeutics. MarketBeat recorded 11 mentions for AbCellera Biologics and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.93 beat AbCellera Biologics' score of 0.53 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kymera Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AbCellera Biologics
2 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

61.4% of AbCellera Biologics shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

AbCellera Biologics has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera Therapeutics$39.21M250.60-$311.35M-$3.62N/A
AbCellera Biologics$75.13M42.02-$146.41M-$0.48N/A

AbCellera Biologics has a net margin of -218.54% compared to Kymera Therapeutics' net margin of -285.33%. AbCellera Biologics' return on equity of -15.35% beat Kymera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kymera Therapeutics-285.33% -22.39% -20.48%
AbCellera Biologics -218.54%-15.35%-10.84%

Kymera Therapeutics has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market.

Kymera Therapeutics presently has a consensus target price of $139.16, indicating a potential upside of 20.90%. AbCellera Biologics has a consensus target price of $16.75, indicating a potential upside of 73.31%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.89
AbCellera Biologics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.92

Summary

AbCellera Biologics beats Kymera Therapeutics on 13 of the 17 factors compared between the two stocks.

How does AbCellera Biologics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and AbCellera Biologics (NASDAQ:ABCL) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Vaxcyte has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market.

Vaxcyte has a net margin of 0.00% compared to AbCellera Biologics' net margin of -218.54%. AbCellera Biologics' return on equity of -15.35% beat Vaxcyte's return on equity.

Company Net Margins Return on Equity Return on Assets
VaxcyteN/A -42.04% -36.82%
AbCellera Biologics -218.54%-15.35%-10.84%

AbCellera Biologics has higher revenue and earnings than Vaxcyte. AbCellera Biologics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A-$766.63M-$8.06N/A
AbCellera Biologics$75.13M42.02-$146.41M-$0.48N/A

Vaxcyte currently has a consensus price target of $117.20, suggesting a potential upside of 111.59%. AbCellera Biologics has a consensus price target of $16.75, suggesting a potential upside of 73.31%. Given Vaxcyte's higher probable upside, equities analysts clearly believe Vaxcyte is more favorable than AbCellera Biologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaxcyte
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
AbCellera Biologics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.92

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, AbCellera Biologics had 7 more articles in the media than Vaxcyte. MarketBeat recorded 11 mentions for AbCellera Biologics and 4 mentions for Vaxcyte. AbCellera Biologics' average media sentiment score of 0.53 beat Vaxcyte's score of 0.48 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vaxcyte
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
AbCellera Biologics
2 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

AbCellera Biologics beats Vaxcyte on 12 of the 16 factors compared between the two stocks.

Get AbCellera Biologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABCL vs. The Competition

MetricAbCellera BiologicsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.63B$4.07B$7.75B$11.70B
Dividend YieldN/A3.64%2.48%4.66%
P/E Ratio-20.1423.4832.5328.82
Price / Sales42.0214.917.975.37
Price / CashN/A22.9521.0521.90
Price / Book2.974.004.263.50
Net Income-$146.41M-$24.08M$3.51B$394.12M
1 Month Performance-21.04%-13.57%-10.58%-12.04%
1 Year Performance175.36%-7.97%-4.79%-11.42%

AbCellera Biologics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABCL
AbCellera Biologics
3.9605 of 5 stars
$9.67
-7.7%
$16.75
+73.3%
+183.4%$3.63B$75.13MN/A562
SMMT
Summit Therapeutics
2.4414 of 5 stars
$14.36
-4.7%
$28.61
+99.2%
-39.5%$11.48BN/AN/A265
HALO
Halozyme Therapeutics
4.5578 of 5 stars
$100.09
-0.6%
$108.18
+8.1%
+32.4%$11.40B$1.80B25.45423
BMRN
BioMarin Pharmaceutical
4.2395 of 5 stars
$57.17
+0.8%
$87.22
+52.6%
+15.1%$11.09B$3.22BN/A3,221
KYMR
Kymera Therapeutics
2.4671 of 5 stars
$127.96
+0.6%
$139.16
+8.8%
+78.1%$10.93B$39.21MN/A285

Related Companies and Tools


This page (NASDAQ:ABCL) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners